New hope for Tough-to-Treat head and neck cancers
NCT ID NCT07136545
Summary
This study is testing whether adding a new drug called HCB101 to an existing immunotherapy (pembrolizumab) can help control advanced head and neck cancer that has stopped responding to standard platinum-based chemotherapy. The trial will enroll about 50 adults to first find the safest dose of HCB101, then see how well the combination works at shrinking tumors and improving quality of life. This is an early-stage study focused on safety and initial effectiveness signals.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang-Gung Memorial Hospital(Lin-Kou)
RECRUITINGTaoyuan District, Guishan District, 333, Taiwan
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Taiwan University Hospital
RECRUITINGTaipei, Taipei city, 100, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Taipei Veterans General Hospital
RECRUITINGTaipei, taipei city, 112, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.